Mutant CALR-directed immunotherapy

Current understanding

To be populated as evidence accumulates.

2026-09-30 — Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies in CALR-mutant Myeloproliferative Neoplasms: cross-connection with dmr-001-mutant-calr-antibody: DMR-001 extends the mutant-CALR-directed immunotherapy landscape (vaccines, BiTEs, ADCs, CAR-T, monoclonals) into early-phase antibody monotherapy and ruxolitinib combination testing. (novelty: 4)
2026-09-28 — Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm: cross-connection with mutant-calr-peptide-vaccine: Peptide vaccine is one modality within the broader mutant-CALR-directed immunotherapy landscape (alongside BiTEs/ADCs, CAR-T, and monoclonal antibodies). (novelty: 4)
2026-09-24 — Selective dependency of CALR-mutant myeloproliferative neoplasms on TYK2 signaling.: cross-connection with deucravacitinib-tyk2-mpn: Both selectively target CALR-mutant MPN clones — TYK2 inhibition offers a small-molecule alternative/complement to CALR-directed immunotherapy. (novelty: 5)
2026-09-15 — Type 1 interferon perturbates clonal competition by reshaping human blood development.: cross-connection with interferon-alpha-mechanism-mpn: Finding that CALR-mutant HSCs escape IFNα by resisting inflammatory-myeloid differentiation links IFNα mechanism to the rationale for CALR-directed therapies targeting the same resistant clone. (novelty: 4)